SG11202004336VA - Creatine prodrugs, compositions and methods of use thereof - Google Patents

Creatine prodrugs, compositions and methods of use thereof

Info

Publication number
SG11202004336VA
SG11202004336VA SG11202004336VA SG11202004336VA SG11202004336VA SG 11202004336V A SG11202004336V A SG 11202004336VA SG 11202004336V A SG11202004336V A SG 11202004336VA SG 11202004336V A SG11202004336V A SG 11202004336VA SG 11202004336V A SG11202004336V A SG 11202004336VA
Authority
SG
Singapore
Prior art keywords
compositions
methods
creatine prodrugs
creatine
prodrugs
Prior art date
Application number
SG11202004336VA
Inventor
Yiumo Chan
Emil D Kakkis
Alexandra Trotier-Faurion
William F Brubaker
Arjun Natesan
Paul Lee
Sharyl Fyffe-Maricich
David Lapointe
Mike E Lizarzaburu
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of SG11202004336VA publication Critical patent/SG11202004336VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms
    • C07D317/40Vinylene carbonate; Substituted vinylene carbonates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
SG11202004336VA 2017-12-01 2018-12-03 Creatine prodrugs, compositions and methods of use thereof SG11202004336VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593731P 2017-12-01 2017-12-01
PCT/US2018/063580 WO2019109067A2 (en) 2017-12-01 2018-12-03 Creatine prodrugs, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202004336VA true SG11202004336VA (en) 2020-06-29

Family

ID=66665277

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004336VA SG11202004336VA (en) 2017-12-01 2018-12-03 Creatine prodrugs, compositions and methods of use thereof

Country Status (15)

Country Link
US (3) US11332438B2 (en)
EP (1) EP3717453A4 (en)
JP (2) JP7433226B2 (en)
KR (1) KR102678696B1 (en)
CN (1) CN111417620B (en)
AR (1) AR118403A1 (en)
AU (1) AU2018375199B2 (en)
BR (1) BR112020010805B1 (en)
CA (1) CA3082184A1 (en)
CO (1) CO2020006542A2 (en)
IL (1) IL274701B2 (en)
MX (1) MX2020005707A (en)
SG (1) SG11202004336VA (en)
TW (1) TWI815832B (en)
WO (1) WO2019109067A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI815832B (en) 2017-12-01 2023-09-21 美商奧特吉尼克斯製藥公司 Creatine prodrugs, compositions and methods of use thereof
US11376990B1 (en) 2021-08-13 2022-07-05 Oshkosh Defense, Llc Electrified military vehicle

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0718000B2 (en) 1985-05-15 1995-03-01 日本真空技術株式会社 Method for forming synthetic resin film
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4915952A (en) 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
DK0595894T3 (en) 1991-07-19 1996-05-13 Uniroyal Chem Co Inc Seed film compositions
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
JPH0718000A (en) * 1993-06-18 1995-01-20 Takeda Chem Ind Ltd Novel peptide
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
CA2235350C (en) 1994-11-08 2009-01-06 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
DE69628025T2 (en) 1995-10-11 2004-04-01 Avicena Group, Inc., Cambridge USE OF CREATINE ANALOGS TO TREAT GLUCOSE METABOLISM DISORDERS
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
IT1282650B1 (en) 1996-02-19 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
US6008252A (en) 1996-07-26 1999-12-28 Beale; Paxton K. Method for increasing muscle mass in a mammal
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP1003476B1 (en) 1997-08-11 2004-12-22 ALZA Corporation Prolonged release active agent dosage form adapted for gastric retention
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US20030008007A1 (en) 2001-04-23 2003-01-09 Jose Gutierrez-Rocca Release pharmaceutical construct for gastric retention
US20030013767A1 (en) 2001-07-13 2003-01-16 Samuel Bessman Method of treating weight loss using creatine
US20040219186A1 (en) 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP2005513057A (en) 2001-12-15 2005-05-12 スフェリックス, インコーポレイテッド Bioadhesive drug delivery system with increased gastric retention
US20050202090A1 (en) 2002-01-03 2005-09-15 Clarke Allan J. Novel pharmaceutical dosage forms and method for producing same
DE10221344A1 (en) 2002-05-14 2003-12-04 Hannover Med Hochschule Transgenic rats and their use in animal models for human Huntington's disease as well as nucleic acid constructs, vectors and cells for their generation
CA2486090C (en) * 2002-05-16 2011-07-05 Bayer Cropscience Gmbh Pyridine carboxamide derivatives and their use as pesticides
CA2485989A1 (en) 2002-05-17 2003-11-27 Esperion Therapeutics, Inc. Methods and compositions for the treatment of ischemic reperfusion
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
AU2003238872A1 (en) 2002-06-04 2003-12-19 Avicena Group, Inc. Methods of treating cognitive dysfunction by modulating brain energy metabolism
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
WO2004002445A2 (en) 2002-06-26 2004-01-08 Cadila Healthcare Limited Novel floating dosage form
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
JPWO2005108370A1 (en) 2004-04-16 2008-03-21 味の素株式会社 Benzene compounds
CA2784420C (en) 2004-07-02 2020-11-10 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US20080103202A1 (en) 2004-11-08 2008-05-01 Chris Ferguson Method of preparing creatine ester salts and uses thereof.
US20070012105A1 (en) 2005-07-13 2007-01-18 Barnes-Jewish Hospital Method and apparatus for resistive characteristic assessment
US20070032750A1 (en) 2005-07-15 2007-02-08 Jeffrey Oster Muscle strength assessment system
US20070281996A1 (en) 2006-06-06 2007-12-06 Xenoport, Inc. Creatine prodrugs, compositions and uses thereof
US7683043B2 (en) 2006-06-06 2010-03-23 Xenoport, Inc. Creatine phosphate analog prodrugs, compositions and uses thereof
US20070281909A1 (en) 2006-06-06 2007-12-06 Xenoport, Inc. Creatine phosphate prodrugs, compositions and uses thereof
US20080206170A1 (en) 2006-12-07 2008-08-28 Belinda Tsao Nivaggioli Creatine compositions for skin treatment
WO2008101310A1 (en) 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
WO2008101309A1 (en) 2007-02-20 2008-08-28 Multi Formulations Ltd. Creatine-fatty acids
US7319157B1 (en) * 2007-02-20 2008-01-15 Multi Formulations Ltd. Creatine-fatty acids
US8546369B2 (en) 2008-05-30 2013-10-01 Northern Innovations Holding Corp. Salts of creatine imino sugar amides
WO2010005692A2 (en) 2008-06-16 2010-01-14 E. I. Du Pont De Nemours And Company Insecticidal cyclic carbonyl amidines
EP2269980A4 (en) 2008-12-24 2011-05-18 Vertex Closed Joint Stock Company Creatine amides, a method for the production thereof and an agent exhibiting a neuroprotective action
US20110201558A1 (en) 2009-12-30 2011-08-18 Baylor Research Institute Anaplerotic Therapy for Alzheimer's Disease and the Aging Brain
EP2579867A4 (en) 2010-06-14 2014-03-19 Baylor Res Inst Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
JP5702248B2 (en) 2011-07-28 2015-04-15 三菱製紙株式会社 Nanofiber, method for forming nanofiber, and method for forming nanofiber aggregate
US9434753B2 (en) 2011-09-19 2016-09-06 Gencia Corporation Modified creatine compounds
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
AR091857A1 (en) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc CISTATIONIN-g-LIASA INHIBITORS (CSE)
EP2692719B1 (en) 2012-07-30 2016-06-08 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof
ITTO20121098A1 (en) 2012-12-18 2014-06-19 Univ Degli Studi Genova PROCEDURE FOR SYNTHESIZING CREATINE DERIVATIVES
EP3039068B1 (en) 2013-08-30 2020-12-16 Momentive Performance Materials Inc. Moisture curable compound with amino acids
WO2015069699A1 (en) 2013-11-05 2015-05-14 Ultragenyx Pharmaceutical Inc. Creatine analogs and the use thereof
ITTO20131070A1 (en) 2013-12-24 2015-06-25 Univ Degli Studi Genova THERAPEUTIC APPLICATION OF A CREATINE DERIVATIVE
US9642825B2 (en) 2014-02-27 2017-05-09 4141 Holdings, Llc Bio-available N-acetyl creatine species and compositions thereof
US10493062B2 (en) 2014-09-03 2019-12-03 Lumos Pharma, Inc. Synthesis of cyclocreatine and analogs thereof
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
WO2016110822A1 (en) 2015-01-09 2016-07-14 Universita' Degli Studi Di Genova Carboxylic biacyl creatine derivative, uses and method of synthesis thereof
AR104144A1 (en) 2015-03-30 2017-06-28 Farmington Pharma Dev PROPHARMS OF CREATINE PHOSPHATE ANALOGS, THEIR COMPOSITIONS AND THEIR USES
TWI815832B (en) 2017-12-01 2023-09-21 美商奧特吉尼克斯製藥公司 Creatine prodrugs, compositions and methods of use thereof

Also Published As

Publication number Publication date
US20240092731A1 (en) 2024-03-21
WO2019109067A2 (en) 2019-06-06
EP3717453A4 (en) 2021-07-28
IL274701B2 (en) 2024-07-01
KR102678696B1 (en) 2024-06-27
WO2019109067A3 (en) 2020-03-26
BR112020010805B1 (en) 2024-01-30
CN111417620A (en) 2020-07-14
CA3082184A1 (en) 2019-06-06
JP2024009811A (en) 2024-01-23
BR112020010805A2 (en) 2020-11-10
US11332438B2 (en) 2022-05-17
AR118403A1 (en) 2021-10-06
JP2021505537A (en) 2021-02-18
CN111417620B (en) 2023-08-25
JP7433226B2 (en) 2024-02-19
US20220227703A1 (en) 2022-07-21
TWI815832B (en) 2023-09-21
AU2018375199B2 (en) 2023-03-30
EP3717453A2 (en) 2020-10-07
AU2018375199A1 (en) 2020-05-28
KR20200105833A (en) 2020-09-09
US11753369B2 (en) 2023-09-12
IL274701A (en) 2020-06-30
US20210002211A1 (en) 2021-01-07
IL274701B1 (en) 2024-03-01
MX2020005707A (en) 2020-08-20
TW201927368A (en) 2019-07-16
CO2020006542A2 (en) 2020-06-09

Similar Documents

Publication Publication Date Title
IL272089A (en) Compounds, compositions and methods
SG11202001783YA (en) Oligonucleotide compositions and methods thereof
IL268970A (en) Novel compositions and methods
PT3676297T (en) Compounds, compositions and methods
GB2546350B (en) Compositions and methods
HUE065174T2 (en) Hla-based methods and compositions and uses thereof
ZA201703507B (en) Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
IL268684A (en) Compositions and methods for immunooncology
GB201807325D0 (en) Compositions and methods
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
GB202201861D0 (en) Novel methods and compositions
IL274524A (en) Compositions and methods for aquaculturing
PT3552017T (en) Compounds, compositions and methods
ZA201903928B (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
EP3771709C0 (en) Creatine prodrugs, compositions and methods of use thereof
PL2998311T3 (en) Mixture of alkylglycosides, manufacture and use thereof
HK1247136A1 (en) Compositions comprising 15-hepe and methods of using the same
IL274701A (en) Creatine prodrugs, compositions and methods of use thereof
ZA202004533B (en) Skin-brightening compositions and methods
IL270505B1 (en) Compounds, compositions and methods
GB201512996D0 (en) Compositions and methods
SG11201706369PA (en) Compositions and methods for the treatment of mucositis
GB201522814D0 (en) Compositions and uses thereof
GB201812952D0 (en) Compositions and uses thereof
GB201704298D0 (en) Compositions and methods